BNGO
Bionano Genomics, Inc.
There isn't enough reported data to score BNGO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BNGO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BNGO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BNGO PE Valuation
BNGO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BNGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| -- |
Analysts expect BNGO's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BNGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$150.60 | +$267.00 |
| Q2 2024 | -$312.60 | -$22.20 |
| Q1 2024 | -$372.60 | -$90.60 |
| Q4 2023 | -$408.60 | -$132.60 |
| Q3 2023 | -$417.60 | -$171.60 |
| Q2 2023 | -$290.40 | -$68.40 |
| Q1 2023 | -$282.00 | -$84.00 |
| Q4 2022 | -$276.00 | -$120.00 |
BNGO has the stronger earnings trend. Trailing diluted EPS is down 136% for BNGO versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BNGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3M | +12% |
| Q2 2026 | $8.2M | +21% |
| Q1 2026 | $6.7M | +3.6% |
| Q4 2025 | $8M | -2.6% |
| Q3 2025 | $7.4M | +21% |
| Q2 2025 | $6.7M | -13% |
| Q1 2025 | $6.5M | -26% |
| Q4 2024 | $8.2M | -24% |
BNGO's revenue is recovering but still below its 2023 peak: $8M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -79% | +37 points |
| Q2 2026 | -88% | +28 points |
| Q1 2026 | -118% | +13 points |
| Q4 2025 | -107% | +39 points |
| Q3 2025 | -116% | +607 points |
| Q2 2025 | -116% | +103 points |
| Q1 2025 | -131% | +224 points |
| Q4 2024 | -146% | +87 points |
BNGO's operating margin was −79% last quarter, up 37 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BNGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BNGO on profitability, with a higher operating margin.
BNGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.5M | +$1.4M |
| Q2 2026 | -$4.7M | -$1.2M |
| Q1 2026 | -$5.7M | -$3M |
| Q4 2025 | -$4.2M | +$2.3M |
| Q3 2025 | -$5.9M | +$7.4M |
| Q2 2025 | -$3.5M | +$17.5M |
| Q1 2025 | -$2.8M | +$25.4M |
| Q4 2024 | -$6.5M | +$23.3M |
BNGO has burned cash in almost every quarter: −$19M over the past year, against −$19M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BNGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BNGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +445K shares |
| 1 year | +248% | +8.6M shares |
| 3 years | +2388% | +11.5M shares |
| 5 years | +5312% | +11.8M shares |
BNGO has 12M diluted shares, up 248% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BNGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BNGO Net Leverage
BNGO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BNGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 8.2 | Oversold |
BNGO's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BNGO PE vs Healthcare Sector
BNGO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BNGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.29 | 19% below |
| 20 week MA | $1.24 | 16% below |
| 50 week MA | $1.27 | 18% below |
| 100 week MA | $2.86 | 64% below |
| 200 week MA | $112.3 | 99% below |
BNGO is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BNGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $648.0 | $423.0 | -35% |
| 2021 | $423.0 | $1,944.0 | +360% |
| 2022 | $1,944.0 | $912.0 | -53% |
| 2023 | $912.0 | $113.4 | -88% |
| 2024 | $113.4 | $12.6 | -89% |
| 2025 | $12.6 | $1.52 | -88% |
| 2026 YTD | $1.52 | $1.04 | -32% |
BNGO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.